Imugene Ltd (ASX:IMU) CEO Leslie Chong speaks with Proactive Investors about the significance of presenting the clinical stage immuno-oncology company's lead candidate - the HER-Vaxx cancer vaccine - at the upcoming American Association for Cancer Research 2019 Annual Meeting.
HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
Price: 0.105 AUD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine. The company had a pre-investigational new drug meeting with the US Food and Drug Administration...
Retail & consumer
Retail & consumer
Industry & services
Finance
